Posted by Michael Wonder on 18 Feb 2025
Dupixent (dupilumab) sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
18 February 2025 - If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the US; FDA decision expected by 20 June 2025.
Regeneron Pharmaceuticals and Sanofi today announced that the US FDA has accepted for priority review the supplemental biologics license application for Dupixent (dupilumab) to treat adults with bullous pemphigoid.
